Author:
Martos Natalie,Hall William,Marhefka Alicia,Sedlak Thomas W.,Nucifora Frederick C.
Abstract
Abstract
Background
Neutropenia, a decrease in total number of neutrophils below 1500/mm3 and particularly severe neutropenia, defined as neutrophils less than 500/mm3, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections and death. However, much of the attention on the potential adverse effect is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work. We demonstrate here that paliperidone can also cause neutropenia and therefore clinicians should be aware of this possibility especially during initiation of treatment.
Case presentation
The following report presents the case of a 23-year-old African American male with first episode psychosis who developed neutropenia after initiation of paliperidone. Neutropenia resolved after discontinuation of paliperidone and initiation of an alternative antipsychotic, haloperidol.
Conclusions
This case report demonstrates an example of paliperidone induced neutropenia which resolved with a switch to haloperidol. We conclude that when initiating paliperidone, clinicians should be more aware of the risk of neutropenia. Moreover, neutropenia may be a more common and overlooked issue in patients on antipsychotic medications other than clozapine and increased awareness of comparative risk across antipsychotics could help direct treatment.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health
Reference15 articles.
1. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483–8. https://doi.org/10.1192/bjp.169.4.483.
2. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750–61. https://doi.org/10.1007/s13311-017-0552-9.
3. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl. 3):3–7.
4. Bautista-Quach MA, Liao YM, Hsueh CT. Pancytopenia associated with clonazepam. J Hematol Oncol. 2010;3:24. https://doi.org/10.1186/1756-8722-3-24.
5. Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R, Greenstein D, Overman GP, Rapoport JL, Gogtay N. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23(2):110–6. https://doi.org/10.1089/cap.2011.0136.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献